Header Logo

Connection

Nirav Shah to Male

Back to Details
This is a "connection" page, showing publications Nirav Shah has written about Male.
Nirav Shah
Connection Strength
0.567
Male
  1. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 03 11; 137(10):1416-1423.
    View in: PubMed
    Score: 0.028
  2. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
    View in: PubMed
    Score: 0.027
  3. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.026
  4. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 11; 24(11):1488-1495.
    View in: PubMed
    Score: 0.025
  5. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 02; 19(2):95-102.
    View in: PubMed
    Score: 0.024
  6. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01; 25(1):e33-e38.
    View in: PubMed
    Score: 0.024
  7. TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. Nat Commun. 2018 04 27; 9(1):1696.
    View in: PubMed
    Score: 0.023
  8. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544.
    View in: PubMed
    Score: 0.023
  9. Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1251-60.
    View in: PubMed
    Score: 0.019
  10. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101.
    View in: PubMed
    Score: 0.010
  11. Brain Health Screening in Older Surgical Patients: A Multicenter, Retrospective, Observational Analysis and Survey. Anesth Analg. 2025 Nov 01; 141(5):1097-1106.
    View in: PubMed
    Score: 0.009
  12. Delirium screening and alerting systems for older hospital inpatients. BMC Health Serv Res. 2025 May 07; 25(1):655.
    View in: PubMed
    Score: 0.009
  13. Multicenter Development and Prospective Validation of eCARTv5: A Gradient-Boosted Machine-Learning Early Warning Score. Crit Care Explor. 2025 Apr 01; 7(4):e1232.
    View in: PubMed
    Score: 0.009
  14. Polygenic Score for the Prediction of Postoperative Nausea and Vomiting: A Retrospective Derivation and Validation Cohort Study. Anesthesiology. 2025 Jan 01; 142(1):52-71.
    View in: PubMed
    Score: 0.009
  15. Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial. JAMA Cardiol. 2024 11 01; 9(11):973-981.
    View in: PubMed
    Score: 0.009
  16. Causes, Diagnostic Testing, and Treatments Related to Clinical Deterioration Events Among High-Risk Ward Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1161.
    View in: PubMed
    Score: 0.009
  17. Development and Validation of a Machine Learning Model for Early Detection of Untreated Infection. Crit Care Explor. 2024 Oct 01; 6(10):e1165.
    View in: PubMed
    Score: 0.009
  18. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332.
    View in: PubMed
    Score: 0.009
  19. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
    View in: PubMed
    Score: 0.009
  20. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329.
    View in: PubMed
    Score: 0.009
  21. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
    View in: PubMed
    Score: 0.009
  22. Development and Validation of a Machine Learning COVID-19 Veteran (COVet) Deterioration Risk Score. Crit Care Explor. 2024 Jul 01; 6(7):e1116.
    View in: PubMed
    Score: 0.009
  23. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
    View in: PubMed
    Score: 0.009
  24. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 05 28; 8(10):2327-2331.
    View in: PubMed
    Score: 0.009
  25. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
    View in: PubMed
    Score: 0.009
  26. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May; 59(5):647-652.
    View in: PubMed
    Score: 0.009
  27. Interaction between cold ischemia time and Kidney Donor Profile Index on postrenal transplant outcomes. Am J Transplant. 2024 May; 24(5):781-794.
    View in: PubMed
    Score: 0.009
  28. Predictors of mortality in periprosthetic fractures of the hip: Results from the national PPF study. Injury. 2023 Dec; 54(12):111152.
    View in: PubMed
    Score: 0.008
  29. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
    View in: PubMed
    Score: 0.008
  30. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022 10 25; 328(16):1595-1603.
    View in: PubMed
    Score: 0.008
  31. Identifying High-Risk Subphenotypes and Associated Harms From Delayed Antibiotic Orders and Delivery. Crit Care Med. 2021 10 01; 49(10):1694-1705.
    View in: PubMed
    Score: 0.007
  32. Determining the Electronic Signature of Infection in Electronic Health Record Data. Crit Care Med. 2021 07 01; 49(7):e673-e682.
    View in: PubMed
    Score: 0.007
  33. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):e775-e781.
    View in: PubMed
    Score: 0.007
  34. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
    View in: PubMed
    Score: 0.007
  35. The Development and Validation of a Machine Learning Model to Predict Bacteremia and Fungemia in Hospitalized Patients Using Electronic Health Record Data. Crit Care Med. 2020 11; 48(11):e1020-e1028.
    View in: PubMed
    Score: 0.007
  36. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
    View in: PubMed
    Score: 0.007
  37. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology. 2020 06; 132(6):1371-1381.
    View in: PubMed
    Score: 0.007
  38. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749.
    View in: PubMed
    Score: 0.007
  39. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 07 03; 2(7):e196476.
    View in: PubMed
    Score: 0.006
  40. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 06 11; 3(11):1661-1669.
    View in: PubMed
    Score: 0.006
  41. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
    View in: PubMed
    Score: 0.006
  42. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 07; 25(7):1456-1464.
    View in: PubMed
    Score: 0.006
  43. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.006
  44. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962.
    View in: PubMed
    Score: 0.006
  45. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04; 25(4):827-833.
    View in: PubMed
    Score: 0.006
  46. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
    View in: PubMed
    Score: 0.006
  47. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517.
    View in: PubMed
    Score: 0.006
  48. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 08; 24(8):1610-1614.
    View in: PubMed
    Score: 0.006
  49. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09; 53(9):1210-1213.
    View in: PubMed
    Score: 0.006
  50. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08; 24(8):1664-1670.
    View in: PubMed
    Score: 0.006
  51. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 04; 103(4):717-727.
    View in: PubMed
    Score: 0.006
  52. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 01; 24(1):78-85.
    View in: PubMed
    Score: 0.006
  53. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960.
    View in: PubMed
    Score: 0.005
  54. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):305-311.e2.
    View in: PubMed
    Score: 0.005
  55. Cerebral Microbleeds, Vascular Risk Factors, and Magnetic Resonance Imaging Markers: The Northern Manhattan Study. J Am Heart Assoc. 2016 09 16; 5(9).
    View in: PubMed
    Score: 0.005
  56. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun; 26(6):616-22.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.